AI-Powered Anti-Fibrotic Drug Reaches Clinical Trials in Record 30 Months
Insilico Medicine transitions into a clinical-stage biotech company as its AI-discovered and AI-designed anti-fibrotic drug enters Phase I clinical trials. The milestone marks a record-breaking 30-month journey from initial target discovery to human testing.
Insilico Medicine officially transitions into a clinical-stage biotechnology company as its first AI-discovered and AI-designed anti-fibrotic drug candidate enters a Phase I clinical trial. This groundbreaking milestone follows the successful completion of a Phase 0 clinical study, proving the viability of the company's end-to-end artificial intelligence platform, Pharma.AI™.
The entire development process takes under 30 months from the initial target discovery program to the start of Phase I trials. This unprecedented speed sets a new standard for therapeutic asset development in the pharmaceutical industry, drastically cutting down the traditional years-long timeline typically required to bring a new drug to human testing.
This specific drug candidate targets Idiopathic Pulmonary Fibrosis (IPF) and tackles a novel biological target identified entirely by artificial intelligence. Exactly one year prior to this clinical milestone, Insilico announced the preclinical candidate nomination after just 18 months of AI-driven target discovery and molecule generation, showcasing a remarkable dual success for AI in modern medicine.